Nanoptima

Executive Summary

NanOptima is a UK-based biotechnology company pioneering controlled-release drug depots to address the high burden of frequent intraocular injections in retinal diseases. Founded in 2015, the company's proprietary technology aims to create long-acting therapeutics that can radically improve the standard of care for conditions such as age-related macular degeneration and diabetic retinopathy. By extending the duration of drug release, NanOptima's approach has the potential to reduce injection frequency from monthly or bi-monthly to once every several months, enhancing patient compliance and clinical outcomes. Currently in the pre-clinical stage, NanOptima is focused on advancing its lead candidates through in vivo efficacy and safety studies. The company's technology platform holds promise for multiple therapeutic payloads, positioning it for potential partnerships with larger pharmaceutical companies specializing in ophthalmology. Key upcoming milestones include completion of key preclinical studies, which will be critical for supporting an IND application and initiating first-in-human trials.

Upcoming Catalysts (preview)

• Q4 2026Completion of lead candidate preclinical efficacy studies60% success
• H1 2027Announcement of strategic partnership or licensing deal40% success
• H2 2027Filing of IND/CTA for first-in-human trial30% success